<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04865536</url>
  </required_header>
  <id_info>
    <org_study_id>TBI-223-CL-002</org_study_id>
    <nct_id>NCT04865536</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Include A Single Dose Food-Effect Study to Evaluate the Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Alliance for TB Drug Development</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Alliance for TB Drug Development</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Partially-Blinded, Placebo-Controlled, Randomized, Multiple Ascending Dose Study&#xD;
      to Include A Single Dose Food-Effect Study to Evaluate the Safety, Tolerability, and the PK&#xD;
      Profile of TBI-223 in Healthy Subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a partially-blinded, placebo-controlled, randomized multiple ascending dose (MAD)&#xD;
      study to be conducted at one study center. Thirty-six (36) subjects will be enrolled in 3&#xD;
      cohorts with 12 subjects per cohort. Within each cohort, 9 subjects will be assigned to&#xD;
      receive active treatment and 3 subjects will receive placebo. Each subject will participate&#xD;
      in one dose level. The first 2 cohorts (food-effect cohorts) will begin dosing of TBI-223 on&#xD;
      Day 1 under fasted conditions, followed by a 3 day washout period and then by multiple doses&#xD;
      of TBI-223 administered after a high-calorie, high-fat meal from Day 4 through Day 17 (total&#xD;
      of 14 days). The third cohort (nonfood- effect cohort) will begin dosing of TBI-223 on Day 1&#xD;
      and continue through Day 14, all doses administered after a high-calorie, high-fat meal. Each&#xD;
      subject will be administered TBI-223 tablets (SR1 or IR or a combination of both&#xD;
      formulations) or placebo once daily for 14 days with corresponding pharmacokinetic&#xD;
      measurements. After each dose cohort, the Sponsor and Investigator will review the&#xD;
      pharmacokinetic and safety data before proceeding to the next dose level. Dose escalation to&#xD;
      the next cohort (i.e., dose level) or decisions regarding changed or additional cohorts will&#xD;
      not take place until the Sponsor, in conjunction with the Principal Investigator and dose&#xD;
      escalating committee, has determined that adequate safety, tolerability, and pharmacokinetics&#xD;
      from the previous cohort(s) have been demonstrated to permit proceeding to the next cohort.&#xD;
      Additional cohorts (up to 12 subjects per cohort) may be enrolled if deemed appropriate by&#xD;
      the Sponsor to study other dose levels, change proposed cohorts, or to study a different&#xD;
      dosage formulation The Institutional Review Board (IRB) should be immediately notified of the&#xD;
      dose escalation or any revised approach for review and approval. Safety will be assessed&#xD;
      throughout the study for all subjects. Safety assessments will include physical and detailed&#xD;
      neurological examinations, vital signs (blood pressure, pulse rate, respiration rate,&#xD;
      temperature and pulse oximetry), electrocardiograms (ECGs), cardiac monitoring, adverse&#xD;
      events (AEs), and clinical laboratory tests (including hematology, serology, serum chemistry,&#xD;
      coagulation, and urinalysis). Blood and urine will be collected for clinical laboratory&#xD;
      evaluations. The Principal Investigator, in conjunction with the Sponsor may collect&#xD;
      additional blood if necessary, for repeat laboratory or safety evaluations including AE&#xD;
      follow up. Female subjects will have blood collected for serum pregnancy testing. Females&#xD;
      claiming postmenopausal status will have blood collected to measure follicle stimulating&#xD;
      hormone (FSH) levels.&#xD;
&#xD;
      During each cohort, blood samples (trough samples) will be obtained before each dose of study&#xD;
      drug, and at the time points on the events schedule. Plasma pharmacokinetic samples will be&#xD;
      analyzed for TBI-223 and M2 using validated analytical methods. Appropriate pharmacokinetic&#xD;
      parameters will be calculated using non compartmental methods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessment Vital Signs - Blood pressure</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>Blood pressure measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessment Vital Signs - Pulse rate</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>Pulse rate measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessment Vital Signs - Respiration rate</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>Respiration rate measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessment Vital Signs - Temperature</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>Temperature measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessment Vital Signs - Pulse oximetry</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>Pulse oximetry measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessment - Cardiac monitoring</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>Safety 12-lead ECGs including ECG QT interval will be recorded and printed for on-site review by the Principal Investigator or designee.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessment - Adverse Events (AEs)</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>AEs recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessment Clinical Laboratory Tests - Hematology</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>Hematology recorded: hemoglobin, hematocrit, total and differential leukocyte count, red blood cell count (RBC), and platelet count.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessment Clinical Laboratory Tests - Serology</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>Serology tests recorded: hepatitis B surface antigen, hepatitis C antibody, and HIV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessment Clinical Laboratory Tests - Serum Chemistry</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>Serum chemistry recorded: albumin, blood urea nitrogen (BUN), creatinine, total bilirubin, alkaline phosphatase (ALP), aspartate transaminase (AST), alanine transaminase (ALT), sodium (Na+), potassium (K+), chloride (Cl-), lactate dehydrogenase (LDH), calcium (Ca), uric acid, glucose, gamma-glutamyltransferase (GGT), and magnesium.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessment Clinical Laboratory Tests - Coagulation</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>Coagulation recorded: prothrombin time (PT), partial thromboplastin time (PTT), and international normalized ratio (INR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessment Clinical Laboratory Tests - Urinalysis</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>Urinalysis recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessment - Serum Pregnancy Testing</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>Blood collection from female subjects for serum pregnancy testing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessment - Follicle-stimulating hormone (FSH) Levels</measure>
    <time_frame>through study completion, 12 weeks.</time_frame>
    <description>Blood collection from postmenopausal women to measure FSH levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - AUCtau</measure>
    <time_frame>Day 1</time_frame>
    <description>AUCtau measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - Cmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Cmax measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - C24</measure>
    <time_frame>Day 1</time_frame>
    <description>C24 measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - Cavg</measure>
    <time_frame>Day 1</time_frame>
    <description>Cavg measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - Tmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Tmax measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - AUCinf</measure>
    <time_frame>Day 1</time_frame>
    <description>AUCinf measured if AUCtau ≥ 70% of AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - AUCextrap</measure>
    <time_frame>Day 1</time_frame>
    <description>AUCextrap measured if AUCtau ≥ 70% of AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - CL/F</measure>
    <time_frame>Day 1</time_frame>
    <description>CL/F measured if AUCtau ≥ 70% of AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - Vz/F</measure>
    <time_frame>Day 1</time_frame>
    <description>Vz/F measured if AUCtau ≥ 70% of AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - lambaZ</measure>
    <time_frame>Day 1</time_frame>
    <description>lambaZ measured if AUCtau ≥ 70% of AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - t1/2</measure>
    <time_frame>Day 1</time_frame>
    <description>t1/2 measured if AUCtau ≥ 70% of AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - AUCtau</measure>
    <time_frame>Day 14</time_frame>
    <description>AUCtau measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - Cmax</measure>
    <time_frame>Day 14</time_frame>
    <description>Cmax measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - Cmin</measure>
    <time_frame>Day 14</time_frame>
    <description>Cmin measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - Ctrough</measure>
    <time_frame>Day 14</time_frame>
    <description>Ctrough (i.e., C0) measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - C24</measure>
    <time_frame>Day 14</time_frame>
    <description>C24 measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - Cavg</measure>
    <time_frame>Day 14</time_frame>
    <description>Cavg measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - Tmax</measure>
    <time_frame>Day 14</time_frame>
    <description>Tmax measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - CL/F</measure>
    <time_frame>Day 14</time_frame>
    <description>CL/F measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - Vz/F</measure>
    <time_frame>Day 14</time_frame>
    <description>Vz/F measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - lambaZ</measure>
    <time_frame>Day 14</time_frame>
    <description>lambaZ measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - t1/2</measure>
    <time_frame>Day 14</time_frame>
    <description>t1/2 measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - RAUC</measure>
    <time_frame>Day 14</time_frame>
    <description>RAUC measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, non-food-effect cohorts - RCmax measured.</measure>
    <time_frame>Day 14</time_frame>
    <description>RCmax measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - AUCtau</measure>
    <time_frame>Day 1</time_frame>
    <description>AUCtau measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - AUCextrap</measure>
    <time_frame>Day 1</time_frame>
    <description>AUCextrap measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - AUCinf</measure>
    <time_frame>Day 1</time_frame>
    <description>AUCinf measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Cmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Cmax measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - C24</measure>
    <time_frame>Day 1</time_frame>
    <description>C24 measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Clast</measure>
    <time_frame>Day 1</time_frame>
    <description>Clast measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Tmax</measure>
    <time_frame>Day 1</time_frame>
    <description>Tmax measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Tlast</measure>
    <time_frame>Day 1</time_frame>
    <description>Tlast measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - CL/F</measure>
    <time_frame>Day 1</time_frame>
    <description>CL/F measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Vz/F</measure>
    <time_frame>Day 1</time_frame>
    <description>Vz/F measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - lambaZ</measure>
    <time_frame>Day 1</time_frame>
    <description>lambaZ measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - t1/2</measure>
    <time_frame>Day 1</time_frame>
    <description>t1/2 measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - AUCtau</measure>
    <time_frame>Day 4</time_frame>
    <description>AUCtau measured. lambaZ, t1/2 should be included if AUCtau ≥ 70% of AUCinf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Cmax</measure>
    <time_frame>Day 4</time_frame>
    <description>Cmax measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - C24</measure>
    <time_frame>Day 4</time_frame>
    <description>C24 measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Cavg</measure>
    <time_frame>Day 4</time_frame>
    <description>Cavg measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Tmax</measure>
    <time_frame>Day 4</time_frame>
    <description>Tmax measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - AUCinf</measure>
    <time_frame>Day 4</time_frame>
    <description>AUCinf measured if AUCtau ≥ 70% of AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - AUCextrap</measure>
    <time_frame>Day 4</time_frame>
    <description>AUCextrap measured if AUCtau ≥ 70% of AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - CL/F</measure>
    <time_frame>Day 4</time_frame>
    <description>CL/F measured if AUCtau ≥ 70% of AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Vz/F</measure>
    <time_frame>Day 4</time_frame>
    <description>Vz/F measured if AUCtau ≥ 70% of AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - lambaZ</measure>
    <time_frame>Day 4</time_frame>
    <description>lambaZ measured if AUCtau ≥ 70% of AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - t1/2</measure>
    <time_frame>Day 4</time_frame>
    <description>t1/2 measured if AUCtau ≥ 70% of AUCinf.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - AUCtau</measure>
    <time_frame>Day 17</time_frame>
    <description>AUCtau measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Cmax</measure>
    <time_frame>Day 17</time_frame>
    <description>Cmax measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Cmin</measure>
    <time_frame>Day 17</time_frame>
    <description>Cmin measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Ctrough</measure>
    <time_frame>Day 17</time_frame>
    <description>Ctrough (i.e., C0) measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - C24</measure>
    <time_frame>Day 17</time_frame>
    <description>C24 measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Cavg</measure>
    <time_frame>Day 17</time_frame>
    <description>Cavg measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Tmax</measure>
    <time_frame>Day 17</time_frame>
    <description>Tmax measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - CL/F</measure>
    <time_frame>Day 17</time_frame>
    <description>CL/F measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - Vz/F</measure>
    <time_frame>Day 17</time_frame>
    <description>Vz/F measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - lambaZ</measure>
    <time_frame>Day 17</time_frame>
    <description>lambaZ measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - t1/2</measure>
    <time_frame>Day 17</time_frame>
    <description>t1/2 measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - RAUC</measure>
    <time_frame>Day 17</time_frame>
    <description>RAUC measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, food-effect cohorts - RCmax</measure>
    <time_frame>Day 17</time_frame>
    <description>RCmax measured.</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Cohort 1 TBI-223 1800 mg, fasting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1800 mg, fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 TBI-23 1800, fed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TBI-23 1800, fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Placebo, fed</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Placebo fasting</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 TBI-223, 2400mg,fed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2400mg,fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 TBI-223, 2400 mg fasting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2400 mg fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Placebo, fed</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Placebo, fasting</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, fasting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 3000mg, fed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3000mg, fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 placebo, fed</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, fed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1800 mg TBI-223</intervention_name>
    <description>3 x 600 mg SR1 tablets</description>
    <arm_group_label>Cohort 1 TBI-223 1800 mg, fasting</arm_group_label>
    <arm_group_label>Cohort 1 TBI-23 1800, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2400mg TBI-223</intervention_name>
    <description>3 x 600 mg SR1 tablets and 1 x 600 mg IR tablets</description>
    <arm_group_label>Cohort 2 TBI-223, 2400 mg fasting</arm_group_label>
    <arm_group_label>Cohort 2 TBI-223, 2400mg,fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3000mg TBI-223</intervention_name>
    <description>4 x 600 mg SR1 tablets and 1 x 600 mg IR tablets</description>
    <arm_group_label>Cohort 3 3000mg, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBI-223 Placebo</intervention_name>
    <description>3 x Placebo tablets</description>
    <arm_group_label>Cohort 1 Placebo fasting</arm_group_label>
    <arm_group_label>Cohort 1 Placebo, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBI-223 Placebo</intervention_name>
    <description>4 x Placebo tablets</description>
    <arm_group_label>Cohort 2 Placebo, fasting</arm_group_label>
    <arm_group_label>Cohort 2 Placebo, fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBI-223 Placebo</intervention_name>
    <description>5 x Placebo tablets</description>
    <arm_group_label>Cohort 3 placebo, fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All volunteers must satisfy the following criteria to be considered for study&#xD;
             participation:&#xD;
&#xD;
               1. Understands study procedures and voluntarily provides written informed consent&#xD;
                  prior to the start of any study-specific procedures.&#xD;
&#xD;
               2. Is a healthy adult male or a healthy adult female, 19 to 50 years of age&#xD;
                  (inclusive) at the time of screening.&#xD;
&#xD;
               3. Has a body mass index (BMI) ≥18.5 and ≤32.0 (kg/m2) and a body weight of no less&#xD;
                  than 50.0 kg at the time of screening and check-in.&#xD;
&#xD;
               4. Is medically healthy with no clinically significant screening results, as&#xD;
                  determined by the Principal Investigator (e.g., laboratory profiles are normal up&#xD;
                  to and including Grade 1 per DMID toxicity tables; Appendix 3), medical history,&#xD;
                  vital signs, ECG, or physical/neurological examination findings. Note: If&#xD;
                  exclusionary lab criteria are met, values may be confirmed by repeat evaluation.&#xD;
&#xD;
               5. Has not used tobacco- or nicotine-containing products (including smoking&#xD;
                  cessation products), for a minimum of 6 months before dosing.&#xD;
&#xD;
               6. Females of non-childbearing potential, based on having undergone one of the&#xD;
                  following sterilization procedures at least 6 months before dosing:&#xD;
&#xD;
                    -  Hysteroscopic sterilization.&#xD;
&#xD;
                    -  Bilateral tubal ligation or bilateral salpingectomy;&#xD;
&#xD;
                    -  Hysterectomy; or&#xD;
&#xD;
                    -  Bilateral oophorectomy.&#xD;
&#xD;
                    -  Or is postmenopausal with amenorrhea for at least 1 year before the first&#xD;
                       dose with serum FSH levels consistent with postmenopausal status (i.e.,&#xD;
                       greater than 40 mIU/mL) at screening. Or, if female of childbearing&#xD;
                       potential, must agree to use an allowable form of birth control from&#xD;
                       screening until 14 days after study completion. The following are allowed&#xD;
                       birth control methods for this study:&#xD;
&#xD;
                    -  Vasectomized partner (at least 6 months before dosing);&#xD;
&#xD;
                    -  Non-surgical permanent sterilization (e.g., Essure® procedure) at least 3&#xD;
                       months before dosing.&#xD;
&#xD;
                    -  Double barrier method (e.g., diaphragm with spermicide; condoms with&#xD;
                       spermicide).&#xD;
&#xD;
                    -  Intrauterine device (IUD).&#xD;
&#xD;
                    -  Abstinence (and must agree to use a double barrier method if they become&#xD;
                       sexually active during the study);&#xD;
&#xD;
                    -  Implanted or intrauterine hormonal contraceptives in use for at least 6&#xD;
                       consecutive months before study dosing; and/or&#xD;
&#xD;
                    -  Oral, patch, or injected contraceptives, or vaginal hormonal device (i.e.&#xD;
                       NuvaRing®), in use for at least 3 consecutive months before study dosing.&#xD;
&#xD;
               7. If a non-vasectomized male (or male vasectomized less than 120 days prior to&#xD;
                  study start) must agree to the following during study participation and for 90&#xD;
                  days after the last administration of study drug:&#xD;
&#xD;
                    -  Use a condom with spermicide while engaging in sexual activity or be&#xD;
                       sexually abstinent&#xD;
&#xD;
                    -  Not donate sperm during this time. In the event the sexual partner is&#xD;
                       surgically sterile or postmenopausal, use of a condom with spermicide is not&#xD;
                       necessary. None of the birth control restrictions listed above are required&#xD;
                       for vasectomized males whose procedure was performed more than 120 days&#xD;
                       before study start.&#xD;
&#xD;
               8. Is willing to answer inclusion and exclusion criteria questionnaire at check-in.&#xD;
&#xD;
               9. Is able to comply with the protocol and the assessments therein, including all&#xD;
                  restrictions.&#xD;
&#xD;
              10. Is willing and able to remain in the study unit for the entire duration of the&#xD;
                  assigned confinement period(s), return for outpatient visit(s), and receive a&#xD;
                  phone call for follow-up questioning about AEs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Volunteers will be excluded from study participation for any of the following:&#xD;
&#xD;
               1. History or presence of clinically significant cardiovascular, pulmonary, hepatic,&#xD;
                  renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
                  neurological (including epilepsy), oncologic, or psychiatric disease or any other&#xD;
                  condition that, in the opinion of the Investigator, would jeopardize the safety&#xD;
                  of the subject or the validity of the study results.&#xD;
&#xD;
               2. Any abnormality on neurologic exam.&#xD;
&#xD;
               3. History of any illness that, in the opinion of the Investigator, might confound&#xD;
                  the results of the study or pose an additional risk to the subject by their&#xD;
                  participation in the study.&#xD;
&#xD;
               4. Surgery within the past 90 days prior to dosing as determined by the Investigator&#xD;
                  to be clinically relevant, or any history of cholecystectomy.&#xD;
&#xD;
               5. History or presence of alcoholism or drug abuse within the past 2 years as&#xD;
                  determined by the Investigator to be clinically relevant.&#xD;
&#xD;
               6. History of sensitivity or contraindication to use of linezolid, tedizolid, or any&#xD;
                  study investigational products.&#xD;
&#xD;
               7. Participation in another clinical trial within 30 days prior to dosing.&#xD;
&#xD;
               8. Female subjects who are pregnant or lactating.&#xD;
&#xD;
               9. Positive result on a urine drug/alcohol/cotinine screen at Baseline or check-in.&#xD;
&#xD;
              10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at&#xD;
                  screening. Out-of-range vital signs may be repeated once for confirmation.&#xD;
&#xD;
              11. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.&#xD;
                  Out-of-range vital signs may be repeated once for confirmation.&#xD;
&#xD;
              12. Any clinically significant ECG abnormality at Screening (as deemed by decision of&#xD;
                  the Investigator and the Sponsor's Medical Monitor). NOTE: The following may be&#xD;
                  considered not clinically significant without consulting the Sponsor's Medical&#xD;
                  Monitor:&#xD;
&#xD;
                    -  Mild first-degree A-V block (P-R interval &lt;0.23 sec)&#xD;
&#xD;
                    -  Right or left axis deviation&#xD;
&#xD;
                    -  Incomplete right bundle branch block&#xD;
&#xD;
                    -  Isolated left anterior fascicular block (left anterior hemiblock) in younger&#xD;
                       athletic subjects&#xD;
&#xD;
                    -  Early repolarization&#xD;
&#xD;
                    -  Tall T waves&#xD;
&#xD;
                    -  RSR in V1/V2 consistent with right ventricular conduction delay (with&#xD;
                       acceptable QRS)&#xD;
&#xD;
                    -  Sinus rhythm or sinus bradycardia with sinus arrhythmia&#xD;
&#xD;
                    -  Minimal or moderate voltage criteria for left ventricular hypertrophy (LVH).&#xD;
&#xD;
              13. QTcF interval &gt;450 msec for males or &gt;470 msec for females at screening, Day -1,&#xD;
                  or Day 1 (predose), or history of prolonged QT syndrome. For the triplicate ECGs&#xD;
                  taken at screening and on Day -1, the average QTcF interval of the three ECG&#xD;
                  recordings will be used to determine qualification.&#xD;
&#xD;
              14. Family history of long-QT syndrome or sudden death without a preceding diagnosis&#xD;
                  of a condition that could be causative of sudden death (such as known coronary&#xD;
                  artery disease, congestive heart failure, or terminal cancer).&#xD;
&#xD;
              15. History of any of the following:&#xD;
&#xD;
                    -  Serotonin syndrome&#xD;
&#xD;
                    -  Seizures or seizure disorders, other than childhood febrile seizures&#xD;
&#xD;
                    -  Brain surgery&#xD;
&#xD;
                    -  History of head injury in the last 5 years&#xD;
&#xD;
                    -  Any serious disorder of the nervous system particularly one that may lower&#xD;
                       the seizure threshold.&#xD;
&#xD;
              16. Lactose intolerant. Specific Treatments&#xD;
&#xD;
              17. Use of any prescription medication within 14 days prior to dosing.&#xD;
&#xD;
              18. Use of any of the following medications within 30 days before the first dose of&#xD;
                  study drug or during the study drug treatment period: monoamine oxidase (MAO)&#xD;
                  inhibitors (phenelzine, tranylcypromine), tricyclic antidepressants&#xD;
                  (amitriptyline, nortriptyline, protriptyline, doxepin, amoxapine, etc.),&#xD;
                  antipsychotics such as chlorpromazine and buspirone, serotonin re-uptake&#xD;
                  inhibitors (fluoxetine, paroxetine, sertraline, etc.), bupropion, agents known to&#xD;
                  prolong the QTc interval (erythromycin, clarithromycin, astemizole, type Ia&#xD;
                  [quinidine, procainamide, disopyramide] and III [amiodarone, sotalol]&#xD;
                  anti-arrhythmics, carbamazepine, sulfonylureas, and meperidine).&#xD;
&#xD;
              19. Use of any over-the-counter (OTC) medication, including herbal products and&#xD;
                  vitamins, within 7 days prior to dosing, except acetaminophen. Up to 3 grams per&#xD;
                  day of acetaminophen is allowed at the discretion of the Investigator prior to&#xD;
                  dosing.&#xD;
&#xD;
              20. Use of any drugs or substances known to be significant inhibitors of cytochrome&#xD;
                  P450 (CYP) enzymes and/or significant inhibitors or substrates of P-glycoprotein&#xD;
                  (P-gp) and/or organic anion transporting polypeptides (OATP) within 14 days prior&#xD;
                  to the first dose of study drug.&#xD;
&#xD;
              21. Use of any drugs or substances known to be inducers of CYP enzymes and/or Pgp,&#xD;
                  including St. John's Wort, within 30 days prior to the first dose of study drug.&#xD;
&#xD;
              22. Use of any drugs or substance known to lower the seizure threshold. Specific&#xD;
                  Laboratory Abnormalities&#xD;
&#xD;
              23. Serum magnesium, potassium, or calcium laboratory values outside of the normal&#xD;
                  range at screening. If exclusionary lab criteria are met, values may be confirmed&#xD;
                  by repeat evaluation.&#xD;
&#xD;
              24. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B&#xD;
                  surface antigen (HBsAg), or hepatitis C antibodies (HCV).&#xD;
&#xD;
              25. ALT or AST greater than ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Bruinenberg, MD, MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Global Alliance for TB Drug Development</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fran Pappas</last_name>
    <phone>646-616-8664</phone>
    <email>fran.pappas@tballiance.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>TKL Research, Inc.</name>
      <address>
        <city>Fair Lawn</city>
        <state>New Jersey</state>
        <zip>07410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suraj K Saggar, MD</last_name>
      <phone>201-587-0500</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TB</keyword>
  <keyword>Tuberculosis</keyword>
  <keyword>TBI-223</keyword>
  <keyword>Pulmonary Tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

